Novartis drug Pelacarsen that targets Lp(a) cholesterol is in global phase 3 trials. Last year, the company launched ...

New drug shows impressive results against lipoprotein(a), a genetic form of cholesterol that affects millions but remains ...

CHICAGO, IL—An investigational agent given by subcutaneous injection can drastically reduce levels of lipoprotein (a), with ...

Lepodisiran, a new drug, slashed levels of “stealthy cholesterol”—a hidden heart risk affecting 1 in 5 people—by up to 95% in ...

Researchers have discovered an experimental medication that significantly reduces a cholesterol-like particle that can ...

However, with lepodisiran, an experimental medication from drugmaker Eli Lilly, cardiologists may be one step closer to effectively treating the deadly form of cholesterol. Here’s what you need ...

Revolutionary drug Lepodisiran dramatically lowers Lp(a) cholesterol, a major heart attack risk factor. Learn about this ...

This new research confirmed earlier findings showing that the experimental drug — lepodisiran, made by Eli Lilly, who funded the study — can “silence” the main gene responsible for ...

Eli Lilly and Company (NYSE: LLY) today announced positive Phase 2 results for lepodisiran, an investigational small interfering RNA (siRNA) therapy designed to lower the production of lipoprotein ...